logo_ProQR-150x150.png
ProQR Announces First Quarter 2021 Operating and Financial Results
May 06, 2021 07:00 ET | ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022Positive data reported from the Phase 1/2 clinical trial of QR-421a for the...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 04, 2021 07:00 ET | Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Saniona to Present at Multiple Upcoming Investor Conferences
April 26, 2021 08:00 ET | Saniona AB
PRESS RELEASE April 26, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it will participate in multiple upcoming investor...
Saniona presenterar på flera kommande investerarkonferenser
April 26, 2021 08:00 ET | Saniona AB
PRESSMEDDELANDE 26 april 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att Bolaget kommer att medverka vid flera...
Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing Feedback from U.S. FDA
April 21, 2021 19:00 ET | Saniona AB
PRESS RELEASE April 22, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it received feedback from the U.S. Food and Drug...
Saniona uppdaterar tidsplanerna för den kliniska utvecklingen av Tesomet baserat på besked om tillverkningen från FDA
April 21, 2021 19:00 ET | Saniona AB
PRESSMEDDELANDE 22 april 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att ett besked mottagits från det amerikanska...
Saniona Announces Partnership with the Foundation for Prader-Willi Research (FPWR) to Support its Prader-Willi Syndrome (PWS) Clinical Trial with Tesomet
April 19, 2021 08:00 ET | Saniona AB
PRESS RELEASE April 19, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it has entered into a partnership with the Foundation for...
Saniona tillkännager partnerskap med Foundation for Prader-Willi Research (FPWR) för att stödja sin kliniska studie med Tesomet på Prader-Willis syndrom (PWS)
April 19, 2021 08:00 ET | Saniona AB
PRESSMEDDELANDE 19 april 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att ett partnerskap har ingåtts med...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
April 14, 2021 09:00 ET | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021
April 14, 2021 08:00 ET | Saniona AB
PRESS RELEASE April 14, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on...